Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On January 13, 2025, X4 Pharmaceuticals, Inc. (XFOR) announced a licensing agreement with Norgine to commercialize mavorixafor in Europe, Australia, and New Zealand.</li><li>X4 will receive &#8364;28.5 upfront and is eligible to receive up to €226 million in potential regulatory and commercial milestone payments along with tiered, double-digit royalties up to the mid-twenties.</li><li>X4 will manufacture and supply mavorixafor and Norgine will reimburse X4 for CMO costs plus a low teen percentage of the CMO costs.</li></ul>

On January 13, 2025, X4 Pharmaceuticals, Inc. (XFOR) announced a licensing agreement with Norgine to commercialize mavorixafor in Europe, Australia, and New Zealand.X4 will receive &#8364;28.5 upfront and is eligible to receive up to €226 million in potential regulatory and commercial milestone payments along with tiered, double-digit royalties up to the mid-twenties.X4 will manufacture and supply mavorixafor and Norgine will reimburse X4 for CMO costs plus a low teen percentage of the CMO costs.

XFOR: Receives &#8364;28.5 Upfront for Licensing Agreement with Norgine 

X4 Pharmaceuticals

XFOR: Receives &#8364;28.5 Upfront for Licensing Agreement with Norgine

XFOR: Receives €28.5 Upfront for Licensing Agreement with Norgine